YZi Labs has announced the appointment of Jane He as General Partner, where she will spearhead biotech investments while also contributing to the firm’s AI and Web3 strategy.
Key Highlights:
Jane He brings a wealth of experience in biotech and medtech, focusing on cancer therapies, gene editing, metabolic treatments, and AI-driven biotech solutions.
Her background includes an investment leadership role as COO at a Hong Kong-based hedge fund, where she specialized in growth-stage investments in biotech and other innovation-driven sectors.
A Stanford GSB graduate, Jane has a proven track record of identifying disruptive opportunities at the intersection of biotech, AI, and next-generation healthcare technologies.
YZi Labs aims to expand its biotech portfolio, emphasizing AI-driven medical advancements and transformative scientific innovation.
